• EE426 Budget Impact Analysis of Atezolizumab in 1ST Line Treatment for Patients With PD-L1 High Metastatic NSCLC From a French Payor Perspective

    Dec 1, 2022, 00:00

  • MSR139 Safe to Assume? Unpacking Regression Assumptions for Utility Data

    Dec 1, 2022, 00:00

  • RWD74 Real-World Effectiveness of CDK 4/6 Inhibitor as First-Line Treatment in Patients With HR+, HER2- Advanced Breast Cancer in South Korea - Focused on Underrepresented Younger and Older Age

    Dec 1, 2022, 00:00

  • EE568 Tenecteplase or Alteplase for Acute Ischemic Stroke? A Cost-Effectiveness Analysis

    Dec 1, 2022, 00:00

  • EE628 Economic Benefits of Cangrelor in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • EE348 The Cost-Effectiveness of Belimumab for the Treatment of Patients With Systemic Lupus Erythematosus (SLE) in China

    Dec 1, 2022, 00:00

  • EE63 Economic Burden of Respiratory Syncytial Virus in Adults in the United States

    Dec 1, 2022, 00:00

  • OP13 Drug Shortage Concepts Among Stakeholders in Saudi Arabia

    Dec 1, 2022, 00:00

  • HTA264 Why Doesn't Environmental Impact Play a Bigger Role in Health Economic Evaluation and Health Technology Assessment – A Systematic Literature Review

    Dec 1, 2022, 00:00

  • CO96 Real-World (RW) Use of Cladribine Tablets in Portugal: A Two-Year Update of a Cohort Database

    Dec 1, 2022, 00:00

  • MT10 Is Ethnicity an Effect Modifier Between FLT3 Inhibitors and Salvage Therapy for Relapsed and Refractory Acute Myeloid Leukemia?

    Dec 1, 2022, 00:00

  • HPR100 Analysis of the Drug Price Level of Anticancer and Rare Disease Drugs After the Implementation of Economic Evaluation Exemption in South Korea

    Dec 1, 2022, 00:00

  • EPH31 Risk of Hospital Admission or Emergency Department Presentation Due to Diabetes Complications: A Retrospective Cohort Study in Tasmania, Australia

    Dec 1, 2022, 00:00

  • EE464 Is the Willingness to Pay for Years of Life in an Extreme Situation of the COVID Pandemic Closures Similar to the Willingness to Pay in Situations of Ordinary Basis? Comparison by Population Groups

    Dec 1, 2022, 00:00

  • MSR41 Predicting Antimicrobial Resistance in Uncomplicated Urinary Tract Infections Using Machine Learning

    Dec 1, 2022, 00:00

  • HTA215 Comparison of French HTA Parallel Appraisal Performed by the Economic and Public Health Committee (CEESP) and the Transparency Committee (TC) for a Same Product: Are the Conclusions of the Two Committees Consistent?

    Dec 1, 2022, 00:00

  • CO77 Use of Interrupted Time-Series Analyses in Evaluating Health Economic Outcomes Following Implementation of Multilayer Water-Tight Wound Closure in a Primary Total Joint Arthroplasty Population

    Dec 1, 2022, 00:00

  • EPH133 Cross-Sectional Research on the Development of Case Management Approach for Disability Patient Based on the Workability Index and Quality of Life Measures

    Dec 1, 2022, 00:00

  • PCR173 Patient and Carer Involvement (PI) in Real World Data Evidence Generation (RWDEG): Findings From Industry

    Dec 1, 2022, 00:00

  • EE370 Cost Effectiveness Evaluation of Dapagliflozin in the Treatment of Chronic Kidney Disease in Mexico

    Dec 1, 2022, 00:00

  • EE646 Systematic Review on Cost and Healthcare Resource Utilization in Immunoglobulin A Nephropathy (IgAN)

    Dec 1, 2022, 00:00

  • EE664 The Basis for a New Framework to Determine the Cost-Effectiveness Threshold

    Dec 1, 2022, 00:00

  • EE300 Health Care Resource Utilisation (HCRU) and Corresponding Costs of Respiratory Syncytial Virus (RSV) Admissions Before the Age of Two in England

    Dec 1, 2022, 00:00

  • HTA182 Time to Access Pediatric/Adolescent vs Adult Medicinal Products in Greece

    Dec 1, 2022, 00:00

  • PCR220 Attitude Toward HPV Vaccination Among Mothers of Boys and Girls

    Dec 1, 2022, 00:00

  • HTA144 Evolution and Implications of the Portuguese HTA Framework on Added Therapeutic Value in Patients’ Access to Innovation

    Dec 1, 2022, 00:00

  • HSD91 Introducing Time-Driven Activity-Based Costing in Chile: Medium Costs Estimation of Breast Cancer Biopsies in a Public Anatomic Pathology Laboratory

    Dec 1, 2022, 00:00

  • PCR36 Content Validity, Acceptability, and Usability of the Electronic Hidradenitis Suppurativa Symptom Daily Diary and the Electronic Hidradenitis Suppurativa Symptom Questionnaire

    Dec 1, 2022, 00:00

  • EE358 Efficiency of Third-Generation Antiseizure Medications in Spain for Drug-Resistant Epilepsy: A Cost-per-Number Needed to Treat Analysis

    Dec 1, 2022, 00:00

  • HPR203 Terminated NICE Appraisals – A Hidden Driver Behind the UK's Access Challenges?

    Dec 1, 2022, 00:00

  • EPH102 Public Health Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in Chile

    Dec 1, 2022, 00:00

  • HPR118 An Updated Estimate of the Direct Cost of the COVID-19 Pandemic for the Greek Healthcare System

    Dec 1, 2022, 00:00

  • EE466 Budget Impact Analysis of Cemiplimab for First-Line (1L) Advanced Non-Small Cell Lung Cancer (NSCLC) With Programmed Cell Death-Ligand 1 (PD-L1)≥ 50% in Italy

    Dec 1, 2022, 00:00

  • PCR281 Utility Studies in Rare Diseases: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • HPR167 A Comparison of ICER Health-Benefit Price Benchmarks in the United States to Drug Prices in the United Kingdom and France

    Dec 1, 2022, 00:00

  • EE61 Economic Evaluation of Therapies Submitted With Non-Comparative Single Arm Phase II Data: A Comparison of NICE and Has Efficiency Opinions

    Dec 1, 2022, 00:00

  • EE347 Treatment Patterns and Healthcare Resource Utilization (HRU) Among Patients With Multiple Sclerosis (MS) in Germany Treated With Nabiximols Between 2010 and 2020

    Dec 1, 2022, 00:00

  • PCR271 Health-Related Quality of Life (HRQOL) by Line of Treatment, Treatment History, and Disease Status in Patients With Metastatic Urothelial Carcinoma (MUC) in EU-4 and the United Kingdom: Results From a Disease Specific Programme

    Dec 1, 2022, 00:00

  • HTA19 How Are United States ICER’S Evidence Ratings Determined? A Systematic Review of ICER’S Evidence Ratings in Evidence Reports for New Drugs in 2020 and 2021

    Dec 1, 2022, 00:00

  • HTA15 An Evaluation of Health Technology Assessment (HTA) Requirements for Emerging Therapies in Alzheimer’s Disease (AD)

    Dec 1, 2022, 00:00

  • RWD15 A Retrospective Database Study to Describe the Prevalence, Patient Characteristics and Healthcare Burden of Prurigo Nodularis (PN) in England

    Dec 1, 2022, 00:00

  • PCR222 Quality of Life (QOL) in Patients With Depression– A Review of Patient Reported Outcomes Instruments

    Dec 1, 2022, 00:00

  • EPH42 Long-Term Impacts of Air Pollution on Health-Related Quality of Life Among Older Adults in China

    Dec 1, 2022, 00:00

  • EE260 An Early Cost-Effectiveness Analysis of a New Continuous Compartment Pressure Monitoring Device in Tibial Fracture Patients Who Are at Risk of Developing Acute Compartment Syndrome (ACS)

    Dec 1, 2022, 00:00

  • SA65 Future Prophylaxis Strategies in RSV: End of the Status Quo

    Dec 1, 2022, 00:00

  • EE480 Cost-Effectiveness of Empagliflozin for the Treatment of Patients With Heart Failure With Above 40% Ejection Fraction in England

    Dec 1, 2022, 00:00

  • HPR190 Evaluating the Impact of the Entry of IVD-R in the Biopharmaceutical Industry, With a Focus on Evidence Requirements and Time to Launch

    Dec 1, 2022, 00:00

  • MSR64 Utility Analysis Methods: Can One Method Fit It All or Is a Case-By-Case Approach Required?

    Dec 1, 2022, 00:00

  • EE252 Budget Impact of a Minimally Invasive Surgical Treatment for Benign Prostatic Hyperplasia in Spain

    Dec 1, 2022, 00:00

  • HPR202 Use of Real-World Data in Regulatory and Reimbursement Submissions for Personalized Medicines in Europe

    Dec 1, 2022, 00:00

  • EE390 Cost-Effectiveness of the 20-Valent Pneumococcal Conjugate Vaccine vs 15-Valent Pneumococcal Conjugate Vaccine for Adults in Argentina

    Dec 1, 2022, 00:00

  • HTA1 Accounting for Placebo Effects in NICE Technology Appraisals of Biologic Therapies: A Comprehensive Review and Future Recommendations

    Dec 1, 2022, 00:00

  • EE678 Cost Effectiveness of Cognitive Behavioural Therapy for Psychosis Through Reduced Hospitalisation

    Dec 1, 2022, 00:00

  • MT8 A Systematic Literature Review of Published Economic Evaluations for Medical Devices in Cardiovascular Disease

    Dec 1, 2022, 00:00

  • HTA177 Current Developments in the Market Access Conditions for Gene Therapies in Germany

    Dec 1, 2022, 00:00

  • MT43 Evidence Generation of Digital Health Applications in Germany – An Overview of the Status Quo

    Dec 1, 2022, 00:00

  • EE272 A Pragmatic Literature Review on the Economic Cost Burden of Four Key Preventable Diseases in the UK

    Dec 1, 2022, 00:00

  • EE211 Shadow Costs of Systemic Corticosteroid-Related Adverse Events in Ulcerative Colitis: A Pharmacoeconomic Evaluation

    Dec 1, 2022, 00:00

  • CO173 Efficacy and Safety of Daridorexant in Patients With Insomnia: Systematic Review Meta-Analysis of Randomized Controlled Trials

    Dec 1, 2022, 00:00

  • PCR38 To What Extent Are Long-Term Breast Cancer Survivors Subjected to Financial Burden in Germany? Results From a Patient Survey-Based Study

    Dec 1, 2022, 00:00

  • CO79 Post-Acute Myocardial Infarction: 90-Day Outcomes Assessment Becoming More Relevant and Critical Due to Patient Burden and Poor Outcomes

    Dec 1, 2022, 00:00

  • MT23 Use of Real Time Chat Functionality in Decentralized Clinical Trials

    Dec 1, 2022, 00:00

  • EPH5 Impact of the COVID-19 Pandemic on Cervical and Breast Cancer Screening

    Dec 1, 2022, 00:00

  • MSR137 The Impact of the Proportion of Cured and Length of Follow-up on Mixture Cure Models (MCMS): A Simulation Study

    Dec 1, 2022, 00:00

  • RWD129 A Comparison of ICU Admission Rate and Related Cost Among Patients Taking Nirmatrelvir and Ritonavir Combination Versus Molnupiravir for Treatment of Mild to Moderate COVID-19 in the US

    Dec 1, 2022, 00:00

  • MSR25 To Merge Randomized Controlled Trials and Real-World Evidence With Bayesian Network Meta-Regression: A Case Study in Patients With Myelodysplastic Syndromes

    Dec 1, 2022, 00:00

  • HTA117 A Targeted Literature Review Into Incorporating Environmental Impact of Healthcare Into Health Technology Assessments (HTAS)

    Dec 1, 2022, 00:00

  • EE8 Cost of Arthropathic Diseases Therapy: A 5-Year Budget Analysis at National Level

    Dec 1, 2022, 00:00

  • EPH145 Treatment Patterns Among Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Ineligible for Transplantation – A Real-World Study Using French PMSI

    Dec 1, 2022, 00:00

  • Deciding Between SF-6Dv2 Health States: A Think-Aloud Study of Decision-Making Strategies Used in Discrete Choice Experiments

    Dec 1, 2022, 00:00

  • MSR12 Validation of Four EQ-5D-5L Crosswalk Prediction Models From Promis-29 in Patients With Cardiovascular Disease

    Dec 1, 2022, 00:00

  • HTA44 Utilisation of Societal Costs in the NICE HST Approvals Compared to European Agencies

    Dec 1, 2022, 00:00

  • EE363 Long Term Costs Assessment of Oral Therapies for Patients With Relapsing Multiple Sclerosis Based on the Evidence From a Large Real-World Study – Application to a Portuguese National Academic Hospital Center

    Dec 1, 2022, 00:00

  • MSR111 Methodology for Building Physician Target List Using Claims and EHR Data

    Dec 1, 2022, 00:00

  • EPH106 Evaluating Changes in the Diagnostic Setting and Treatment of Bacterial Sexually Transmitted Infections in Germany During COVID-19: A Descriptive Analysis of German Claims Data From 2018-2021

    Dec 1, 2022, 00:00

  • RWD18 Underappreciation of Disease Burden in Female Patients With Axial Spondyloarthritis (AxSpA) in Real-World Care

    Dec 1, 2022, 00:00

  • HPR196 Patient Reported Outcome Measures Are of Profound Importance for the Success of Health Technology Assessments in Oncologic Indications in Germany

    Dec 1, 2022, 00:00

  • HTA189 Implications of the French Temporary Authorisation for Use Reform for the Pharma Industry

    Dec 1, 2022, 00:00

  • EE498 Cost of Follow-Up After an Ischemic Cerebrovascular Event in Patients With Atherosclerotic Cardiovascular Disease in Spain: Results from the Reality Study

    Dec 1, 2022, 00:00

  • HPR213 Comparative Analysis of Access to Advanced Therapy Medicine Products (ATPM) in Latin America

    Dec 1, 2022, 00:00

  • EE431 The Cost-Effectiveness of Home-Based Cardiac Rehabilitation Interventions: A Systematic Review

    Dec 1, 2022, 00:00

  • EE394 Cost-Effectiveness of Alpelisib Plus Fulvestrant for the Treatment of Postmenopausal Women With PIK3CA Mutant, HR+/HER2- Advanced Breast Cancer in Turkey

    Dec 1, 2022, 00:00

  • EE224 Cost-Effectiveness Analysis of Real-Time Continuous Glucose Monitoring (RTCGM) vs Self-Monitoring of Blood Glucose (SMBG) in Patients With Type 1 Diabetes in the Netherlands

    Dec 1, 2022, 00:00

  • EPH93 Drivers of Treatment Decisions in Multiple Myeloma Front-Line Transplant-Eligible Patients in a Real-World Setting: A Qualitative Assessment of Physicians’ Perspectives in Europe

    Dec 1, 2022, 00:00

  • PCR52 Adherence/Compliance to HIV–1 Treatment Regimens in South Africa — A Targeted Literature Review

    Dec 1, 2022, 00:00

  • HPR113 Health Metrics and Theories of Health Value

    Dec 1, 2022, 00:00

  • HTA234 Impact of Cost-Effectiveness Assessment Scheme (as a Part of HTA System) on Drug Prices in Japan

    Dec 1, 2022, 00:00

  • HPR147 Evaluating the Misdiagnosis of Add in Patients With Prior History of Depression: A Claims Data Study in Germany

    Dec 1, 2022, 00:00

  • PCR163 Humanistic and Economic Burden of Pyruvate Kinase Deficiency: A Systematic Review of Literature

    Dec 1, 2022, 00:00

  • HTA161 A Systematic Review of the Safety of COVID-19 Anti-Interleukin Therapy

    Dec 1, 2022, 00:00

  • HPR110 ESG in Pharma Procurement, Not More Than Wishful Thinking? A Quantitative View on Award Criteria in Tenders in the EU5 From 2011 to 2020

    Dec 1, 2022, 00:00

  • PCR57 An Empirical Comparison of Data From Forced vs Non-Forced Choices in a Dual Response Discrete Choice Experiment, With Breast Cancer Patients in Six European Countries

    Dec 1, 2022, 00:00

  • PCR27 Pediatric Outcomes Data Collection Instrument (PODCI) Assessment of Ambulatory Boys Treated With Fordadistrogene Movaparvovec (PF-06939926) for Duchenne Muscular Dystrophy (DMD)

    Dec 1, 2022, 00:00

  • PCR261 Elicitation of Health Utilities Online in Patients With Spinal Muscular Atrophy

    Dec 1, 2022, 00:00

  • MSR34 Forecasting the Long-Term Treatment Effect Duration of Immuno-Oncology Therapies: An Analysis of the Predictive Accuracy of Treatment Waning Methods Applied to Pembrolizumab in Non-Small Cell Lung Cancer

    Dec 1, 2022, 00:00

  • EE476 Budget Impact Analysis of iGlarLixi for Treatment of T2DM in Algerian Setting

    Dec 1, 2022, 00:00

  • EPH146 Inequitable Access to Cannabis Vaping Products Across Canada: Examining Consumer Preferences

    Dec 1, 2022, 00:00

  • PCR162 Patient and Physician Perspectives Towards Current HIV Treatment Satisfaction and the Use of Long-Acting Injectable Therapy for HIV in Taiwan

    Dec 1, 2022, 00:00

  • HTA169 Health Technology Assessment and Reimbursement for Select Oncology Therapies in European Major Markets

    Dec 1, 2022, 00:00

  • HPR79 A Qualitative Exploration of Drivers of Cannabis Purchase Decisions in Canada

    Dec 1, 2022, 00:00

  • EE310 Cost-Effectiveness of the Prenatal Detection of Congenital Heart Diseases: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • CO169 Assessing Parameters and Microbiological Factors Affecting Phlebitis Associated With Peripheral Cannulas

    Dec 1, 2022, 00:00

  • EPH28 Underage Drinking in Adolescents

    Dec 1, 2022, 00:00

  • EPH190 Premature Mortality From Ischaemic Heart Disease Among Men in Hungary by District

    Dec 1, 2022, 00:00

  • PCR127 Impact of Dry Eye on Daily Life and Patient Satisfaction Using Eye Drops. Psychometrics Properties of a New Scale

    Dec 1, 2022, 00:00

  • EE186 Assessment of the Cost-Effectiveness of Secukinumab Versus Risankizumab for the Treatment of Adults With Moderate-to-Severe Plaque Psoriasis in the UK

    Dec 1, 2022, 00:00

  • PCR93 Improving the Methods of Vignette Development for Utility Estimation: A Case Study in Pompe Disease

    Dec 1, 2022, 00:00

  • EPH87 Safety of Interchanging From Reference Biologic to its Biosimilar: A Systematic Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • EPH34 Long COVID Symptoms and Diagnosis in Primary Care: A Cohort Study Using the Thin Database Including Unstructured Text

    Dec 1, 2022, 00:00

  • PCR123 Assessment of Drug-Drug Interactions in Criticalcare Unit of a Tertiary Care Hospital

    Dec 1, 2022, 00:00

  • MSR119 Does Federated Analytics Preserve Statistical and Scientific Value of Real-World Data?

    Dec 1, 2022, 00:00

  • PCR285 Burden of Itch Among Patients With Chronic Kidney Disease/End-Stage Kidney Disease Receiving Hemodialysis: Results From a Prospective Patient-Reported Survey in the USA

    Dec 1, 2022, 00:00

  • P46 How Are European Countries Assessing Digital Health Technologies (DHTS)? A Comparison of DHT Health Technology Assessments (HTAS) Across France, Germany and the UK

    Dec 1, 2022, 00:00

  • PCR227 Psoriasis and Alterations in Quality of Life at Work: A Study Cross-Referencing Real-World Data From Two Sources—Medical Consultations and Social Networks

    Dec 1, 2022, 00:00

  • PCR203 A Review of the Quality-of-Life Data Use in French Economic and Public Health Assessment Committee’s (CEESP) Efficiency Opinions for Immune-Checkpoint Inhibitors (ICIS) and Chimeric Antigen Receptor T (CAR-T CELL THERAPIES)

    Dec 1, 2022, 00:00

  • HPR140 Assessing the Influence of the Orphan Drug Status on Medicine Prices in the EU4 + UK

    Dec 1, 2022, 00:00

  • EE115 Cost-Effectiveness and Cost-Utility Analyses of Polatuzumab Vedotin With Rituximab and Chemotherapy vs Rituximab and Chemotherapy in Treating Naïve Diffuse Large B-Cell Lymphoma in Italy

    Dec 1, 2022, 00:00

  • HSD87 Exploring the Treatment Patterns of Bipolar Disorder Using the Observational Medical Outcomes Partnership Common Data Model

    Dec 1, 2022, 00:00

  • EE472 Use of Health Resources and Micro-Costing Analysis of Hospitalization for Bronchiolitis and Pneumonia in Pediatric Patients: A Retrospective Study From Brazilian Perspective

    Dec 1, 2022, 00:00

  • EE178 Cost-of-Illness Analysis of Pertussis Among Adults 50 Years of Age and Older in the United Kingdom

    Dec 1, 2022, 00:00

  • HPR131 Benefit Package of Universal Coverage Scheme for Hereditary Angioedema (HAE) Caused by C1 Esterase Inhibitor Deficiency (C1-INH)

    Dec 1, 2022, 00:00

  • EPH3 Could We Continue CXR Screening for Lung Cancer: Re-Evaluation of CXR Screening With Background Consideration

    Dec 1, 2022, 00:00

  • CO129 Effectiveness of a Prescription Digital Therapeutic of Cognitive-Behavioral Therapy for Insomnia in 2 Clinical Trials and in Real-World Clinical Settings: A Number Needed to Treat Analysis

    Dec 1, 2022, 00:00

  • SA22 Examination of Correlations Between Core Stability, Low Back Pain and Stress in the Staff of the Hungarian National Ambulance Service

    Dec 1, 2022, 00:00

  • EE668 Empagliflozin for the Treatment of Adult Patients With Symptomatic Chronic Heart Failure With Reduced Ejection Fraction (HFREF): A Cost-Effectiveness Analysis From the Italian NHS Perspective

    Dec 1, 2022, 00:00

  • HTA14 Health Economic Evaluation of Nation-Wide Screening Programmes for Atrial Fibrillation in the Netherlands

    Dec 1, 2022, 00:00

  • HTA52 Evaluation of Cost by TPS vs Pharmacotherapy of Dementia in Ukraine

    Dec 1, 2022, 00:00

  • EE634 Disease Burden Analysis of Prophylactic Treatment Versus On-Demand Treatment for Adult Patients With Moderate-to-Severe Haemophilia A in China

    Dec 1, 2022, 00:00

  • RWD144 Real World Data (RWD) Sharing Internationally: Case Digital Twin (DT) in Inflammatory Bowel Disease (IBD)

    Dec 1, 2022, 00:00

  • EE230 Clinical and Economic Outcomes Associated With Use of Anti-Arrhythmic Drugs Versus Ablation in Atrial Fibrillation (AFib)

    Dec 1, 2022, 00:00

  • EE313 Intensity of Colorectal Cancer Screening Strategies and the Optimal Policy Choi A Systematic Review of European Cost Effectiveness Analyses

    Dec 1, 2022, 00:00

  • MSR16 Mixture-Cure Modelling of Overall Survival of Patients With Metastatic Non-Small Cell Lung Cancer Receiving Nivolumab + Ipilimumab in CheckMate 277 – Updated With 5 Years of Follow-up

    Dec 1, 2022, 00:00

  • HSD6 Developing a Risk-Stratification Dashboard Based in Artificial Intelligence (AI) to Identify Patients for a Model of Health Care: A Population-Based Cohort Study in Brazil

    Dec 1, 2022, 00:00

  • EE609 The Cost of Beta Thalassemia Major Disease From Patient Perspective in Egypt

    Dec 1, 2022, 00:00

  • HPR133 Impact of International Reference Pricing (IRP) on Medicines Reimbursement Prices in Bosnia and Herzegovina

    Dec 1, 2022, 00:00

  • RWD23 Healthcare Disparity in Change in Clinical Outcomes in Multiple Myeloma Patients

    Dec 1, 2022, 00:00

  • SA23 Application of Meta-Analysis Approach to Develop an External Control Arm in Oncology and Rare Diseases: Insights From Real-World Evidence

    Dec 1, 2022, 00:00

  • HTA57 Recommendations for Evidence Generation Activities Supportive of National HTA in the South African Public Health Sector

    Dec 1, 2022, 00:00

  • EE552 Slovenian EQ-5D-5L Value Set

    Dec 1, 2022, 00:00

  • MSR131 Characterizing the Impact of the Shared-Effect Modification Assumption on Population-Adjusted Indirect Comparisons

    Dec 1, 2022, 00:00

  • EE648 Economic Analysis of New Single-Inhaler Triple Therapies in Patients With COPD in the UK

    Dec 1, 2022, 00:00

  • HPR37 Comparing Reimbursement of New Drugs During the COVID-19 Pandemic in Ireland and Scotland

    Dec 1, 2022, 00:00

  • EE504 The Economic Burden of Migraine in Spain: A Nationwide Cost-of-Illness Approach From the Year 2020 European Health Survey in Spain

    Dec 1, 2022, 00:00

  • EE548 Value Based Reimbursement Decision Making Parameters for Acute on Chronic Liver Failure – Potential Evaluation Framework on Acute Rare Diseases

    Dec 1, 2022, 00:00

  • EE662 Cost-Effectiveness of Iron Chelation Therapies for the Treatment of Transfusional Iron Overload in Β-Thalassaemia, Sickle Cell Disease, and Myelodysplastic Syndrome: A Literature Review

    Dec 1, 2022, 00:00

  • RWD90 Chart Review Study for Patients With Sickle Cell Disease With Central Nervous System Crises in Jazan – Saudi Arabia

    Dec 1, 2022, 00:00

  • MSR68 Development of a Checklist for Studies Reporting the Elicitation of Stated Preferences Values for Child Health Related Quality of Life

    Dec 1, 2022, 00:00

  • EE239 Real-World Analysis and Economic Evaluation of the Freestyle Libre System in Selected Districts in Italy: The Reconnect Study

    Dec 1, 2022, 00:00

  • CO83 Reduction of Transfusion Requirements and Length of Hospital Stay in Patients Undergoing Major Planned Surgery After the Implementation of Patient Blood Management (PBM) in Spain

    Dec 1, 2022, 00:00

  • HSD96 Burden of Patient Journey in the Management of Alpha-1 Antitrypsin Deficiency in Spain

    Dec 1, 2022, 00:00

  • PCR43 Comparison of Face-to-Face and Online Surveys of Measuring Utility for Metastatic Pancreatic Cancer in Japan Using Composite Time Trade-Off

    Dec 1, 2022, 00:00

  • HPR73 A Comparison of the Evolution of Payer Management Practices in Oncology in the United States, Germany, France, and the United Kingdom, Over the Past Five Years

    Dec 1, 2022, 00:00

  • PCR252 Patient and Caregiver Burden Associated With Caring for a Child With Alagille Syndrome: Mixed-Methods Development of Health State Vignettes

    Dec 1, 2022, 00:00

  • EE388 Cost Effectiveness of Novel Antibiotic Ceftolozane/Tazobactam in Patients With Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia in Greece

    Dec 1, 2022, 00:00

  • PCR60 Self-Reported Impact of Osteogenesis Imperfecta (OI) on Quality of Life (QOL) Domains in Adults

    Dec 1, 2022, 00:00

  • PCR40 Impact of Non-Pharmacological Interventions on Medication Adherence in Hypertension or Dyslipidemia: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • MSR104 Assessing the Impact of Integrating Extrapolated Long-Term Outcomes Into Elicitation of Unreported Subgroup-Specific Survival in Randomized Controlled Trials (RCTS): Insights From Advanced Stage Gastrointestinal Cancers

    Dec 1, 2022, 00:00

  • EPH2 Development and Validation of Clinical Prediction Score of Mortality in Tuberculosis Patients

    Dec 1, 2022, 00:00

  • EE574 Cemiplimab and Pembrolizumab for Advanced Non-Small Cell Lung Cancer With PD-L1 ≥ 50%: Number Needed to Treat and Cost of Preventing an Event in the Brazilian Private Healthcare System Perspective

    Dec 1, 2022, 00:00

  • HSD5 Patients Satisfaction for Transanal Irrigation and Intermittent Catheterization Service of Delivery

    Dec 1, 2022, 00:00

  • MSR85 Performance Comparison of Unanchored Matching-Adjusted Indirect Comparison and Naïve Treatment Indirect Comparison on Survival Outcomes: A Simulation Study

    Dec 1, 2022, 00:00

  • EE369 Cost-Effectiveness Analysis of Drug Therapies for Diabetes Mellitus Type 2 in Chile

    Dec 1, 2022, 00:00

  • CO76 Value of Axicabtagene Ciloleucel Versus Chemotherapy in the Large B-Cell Lymphoma Treatment: Health Outcomes Based on the Number of Patients Treated in Spain

    Dec 1, 2022, 00:00

  • EE404 Forecast of Social and Economic Burden of HIV-Infection in Russia in Different Scenarios of Anti-HIV Policy up to 2035

    Dec 1, 2022, 00:00

  • EPH33 Assessing the Validity of English Linked Routine Healthcare Resource Utilisation Data in the Investigation of Triple Therapy Effectiveness (INTREPID Trial)

    Dec 1, 2022, 00:00

  • HPR21 Project Orbis the UK: 18-Month Report Card – Implications of UK Market Access for Oncology Drugs Prior to Europe

    Dec 1, 2022, 00:00

  • MSR37 Meaningful Difference in Performance (MDP): A Proposed Method to Improve Evaluation of Meaningful Variation Healthcare Quality Measures

    Dec 1, 2022, 00:00

  • PCR44 A Qualitative Study of Measuring Health Related Quality of Life in Migraine Patients: Comparing EQ-5D and MSQ V2.1 Questionnaires

    Dec 1, 2022, 00:00

  • Development of the Bleeding and Pelvic Discomfort Scale for Use in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

    Dec 1, 2022, 00:00

  • HPR194 The UK Innovative Licensing and Access Pathway (ILAP) Program – Early Trends in Innovation Passport Awards

    Dec 1, 2022, 00:00

  • EE488 How Is Real-World Data Used in Health Technology Assessments to Inform Reimbursement Decisions for Multiple Sclerosis Drugs? A European Perspective

    Dec 1, 2022, 00:00

  • P32 The Use of 'Placebo Adjusted Risk Difference Network Meta-Analysis' to Account for Confounding by Heterogeneity in Placebo Response Across Studies

    Dec 1, 2022, 00:00

  • MSR95 Use of Generalized F Parameterization in Long-Term Extrapolation for Adjuvant Cancer Therapies

    Dec 1, 2022, 00:00

  • HSD57 The Actionable Gaps of the Journey of Patients With Lung Cancer

    Dec 1, 2022, 00:00

  • SA38 Mortality Estimates in Patients With Anti-Aquaporin-4 Autoantibody Positive Neuromyelitis Optica Spectrum Disorder

    Dec 1, 2022, 00:00

  • EE39 Willingness to Pay for Cancer Prevention, Screening, Diagnosis, and Treatment: A Systematic Review

    Dec 1, 2022, 00:00

  • HTA92 10 Years of AMNOG: Importance of Real-World Evidence Studies in the German Benefit Assessment Process

    Dec 1, 2022, 00:00

  • HTA188 Does Size Matter? Impact of Population Size on Evidence Quality and Negotiation Outcome for Orphan Drugs in Germany

    Dec 1, 2022, 00:00

  • HTA150 RWE in HTA Recommendations for Decision Making: Analysis From Ukrainian Perspective

    Dec 1, 2022, 00:00

  • HSD80 Corporate Environmental and Social Responsibility Applied in a Technical Service Network: Addressing Greener Business, Employee Customer Satisfaction

    Dec 1, 2022, 00:00

  • EE583 Cost-Effectiveness of Dapagliflozin in the Treatment of Chronic Symptomatic Heart Failure With Reduced Ejection Fraction in the Netherlands

    Dec 1, 2022, 00:00

  • RWD44 The Cost of Haemophilia in Adults, a Socioeconomic Survey of People With Severe Haemophilia in Latin America: The ‘Chess Latam’ Study

    Dec 1, 2022, 00:00

  • P30 Incorporating Beliefs on the Relevance of Values Into Meta-Analyses of Health State Utility Values Using the Bayesian Power Prior

    Dec 1, 2022, 00:00

  • PCR254 Targeted Literature Review of Caregiver Burden and Generational Burden in Depression

    Dec 1, 2022, 00:00

  • PCR224 Acceptability and Usability of the Electronic Hidradenitis Suppurativa Quality of Life Questionnaire

    Dec 1, 2022, 00:00

  • PCR268 The Impact of Radiotherapy Non-Compliance on the Recurrence and Mortality of Breast Cancer Patients: A Systematic Review

    Dec 1, 2022, 00:00

  • HPR105 Examining Attributes of Retailers That Influence Where Cannabis Is Purchased

    Dec 1, 2022, 00:00

  • PCR138 Association of SARS-CoV-2 Omicron Ba.1 on Adherence to Oral Tetrabenazine Congener and Quality of Life of Patients Diagnosed With Huntington's Disease With Chorea or Tardive Dyskinesia on the Service of a USA Specialty Pharmacy

    Dec 1, 2022, 00:00

  • EE663 Estimating the Cost of an Outpatient Department Visit in the Irish Public Health Care System

    Dec 1, 2022, 00:00

  • HPR187 Assessing the Impact of Anti-PD-1/PD-L1 Inhibitors on Cancer Care Health and Budget in Greece

    Dec 1, 2022, 00:00

  • EPH43 Association Between Human Papillomavirus Vaccination and Serious Adverse Events in Females Aged 9 to 26 Years: A Systematic Review and Meta Analysis

    Dec 1, 2022, 00:00

  • PCR284 Fatigue and Health-Related Quality of Life in Paroxysmal Nocturnal Haemoglobinuria (PNH): A Post-Hoc Analysis of Pegcetacoplan Pegasus Facit-Fatigue Trial Data

    Dec 1, 2022, 00:00

  • HTA206 Use of Real-World Data in Systematic Literature Reviews Conducted for Health Technology Assessment Submissions in Europe

    Dec 1, 2022, 00:00

  • EE351 Recognising the Broader Value of Meningococcal Vaccination: A Matter of Evidence, Ability or Willingness?

    Dec 1, 2022, 00:00

  • EE585 Human Capital Loss Associated With Ill-Health: Evidence from Patients With End-Stage Kidney Disease in Taiwan

    Dec 1, 2022, 00:00

  • PCR135 Symptom Burden and Its Impact on Daily Living with Idiopathic Multicentric Castleman’s Disease: Development and Psychometric Validation of a Bespoke International Patient and Caregiver Survey

    Dec 1, 2022, 00:00

  • EPH171 Delivery Outcomes in the United States Among Women With Commercial or Medicaid Insurance During the COVID-19 Pandemic

    Dec 1, 2022, 00:00

  • HTA178 High-Energy Devices and Standard Monopolar/Bipolar Devices: An HTA in the Italian Surgical Setting

    Dec 1, 2022, 00:00

  • PCR184 Urban/Rural Differences in Preferences for EQ-5D-5L Health States: A Study of a Multi-Ethnic Region in China

    Dec 1, 2022, 00:00

  • EE267 Evolution of Country Gross Domestic Product Following the COVID-19 Pandemic

    Dec 1, 2022, 00:00

  • HSD30 Analysis of the Balanced Scorecard's Financial Subdimensions in Health Care Organizations During the COVID-19 Pandemic

    Dec 1, 2022, 00:00

  • CO118 TRK Inhibitor Treatment Patterns in Patients with NTRK Fusion-Positive Solid Tumors: A Multi-Site Cohort Study at U.S. Academic Cancer Centers

    Dec 1, 2022, 00:00

  • HTA73 Evaluation of NICE Severity Modifiers

    Dec 1, 2022, 00:00

  • HTA116 How is Carer Quality of Life Included in Health Technology Assessment Globally? A Review of Guidance, With Case Studies and Recommendations

    Dec 1, 2022, 00:00

  • EE9 Cost-Effectiveness Analysis of Dupilumab, Mepolizumab and Benralizumab for Severe Eosinophilic Asthma With Blood Eosinophil Count ≥300 Cells/Mcl in the Brazilian Private Healthcare Perspective

    Dec 1, 2022, 00:00

  • EE342 Pancreatic Exocrine Insufficiency in Patients Who Have Undergone Surgery Due to Pancreatic Cancer: A Chinese Cost-Utility Analysis

    Dec 1, 2022, 00:00

  • CO94 Tepotinib Compared With Chemoimmunotherapy in First-Line Non-Small Cell Lung Cancer (NSCLC): Matching Adjusted Indirect Comparison (MAIC) of VISION in MET Exon 14 (METex14) Skipping NSCLC and KEYNOTE-189 in Wild-type NSCLC

    Dec 1, 2022, 00:00

  • EE443 Economic Value of Covered Expanded Polytetrafluoroethylene (eptfe) Stent Grafts Compared to Percutaneous Balloon Angioplasty for Treating Thrombosed and Dysfunctional Arteriovenous Grafts in Hemodialysis Patients in Spain

    Dec 1, 2022, 00:00

  • MT11 A Cost-Effectiveness Analysis of Acrysof IQ Vivity Intraocular Lens (IOL) From Private Health Fund Perspective in Australia

    Dec 1, 2022, 00:00

  • HSD12 Reasons for Choice and Areas for Improvements of Advanced Therapies (Biologics and Janus Kinase Inhibitors) for Patients With Ulcerative Colitis in the United Kingdom

    Dec 1, 2022, 00:00

  • EE657 Age and Gender Differences in Direct Non-Health Costs for Formal and Informal Assistance, Costs for Productivity Loss Among Italian Behçet Patients

    Dec 1, 2022, 00:00

  • EE398 Budget Impact Analysis of Lurasidone in the Treatment of Adult and Adolescent Patients With Schizophrenia in Spain

    Dec 1, 2022, 00:00

  • CO122 Mapping the Characteristics of Network Meta-Analyses on Antithrombotic Therapies: An Overview and Critical Appraisal

    Dec 1, 2022, 00:00

  • P24 Improved Estimation of Overall Survival and Progression-Free Survival for State Transition Modelling in Oncology

    Dec 1, 2022, 00:00

  • MSR91 Automated Tools to Support Screening in Literature Reviews: What's Out There for Reviewers?

    Dec 1, 2022, 00:00

  • CO145 Sensitivity to Change of the PDQ-Exercise

    Dec 1, 2022, 00:00

  • HTA146 From Vague to Valid – Chances and Risks of Benefit Re-Assessments Due to New Scientific Evidence in Germany

    Dec 1, 2022, 00:00

  • HPR212 Solving the Mystery: Are There Variables That Could Positively Influence PR Approval of Orphan Drugs (ODs) in Spain?

    Dec 1, 2022, 00:00

  • EE665 Cost-Minimisation Analysis of Oral Semaglutide Versus Dulaglutide in Patients With Type 2 Diabetes Requiring Treatment With a GLP-1 Receptor Agonist

    Dec 1, 2022, 00:00

  • MSR36 Modelling of UK General Population Utility: The ALDVMM Approach in Practice

    Dec 1, 2022, 00:00

  • MSR108 Identifying Diabetes Types by Modelling Drug Consumption and Patient Profile Data From Pharmacies

    Dec 1, 2022, 00:00

  • EE586 Cost-Utility of Cladribine Tablets and Dimethyl Fumarate in the Treatment of Relapsing Remitting Multiple Sclerosis From the Societal Perspective in Spain

    Dec 1, 2022, 00:00

  • PCR72 Effects on Employment for Adults Within the Early Stages of Manifest Huntington's Disease: A Cross-Sectional Analysis Using Enroll-HD

    Dec 1, 2022, 00:00

  • MT12 A Targeted Literature Review on Digital Health Innovation (DHI) in Asia Pacific (APAC) Region

    Dec 1, 2022, 00:00

  • HTA33 Does the Selection of Participating Regions Impact the Outcome of Spanish Therapeutic Positioning Reports?

    Dec 1, 2022, 00:00

  • HTA46 Outcomes of Benefit Assessments of Orphan Drugs Without Orphan Designation in Germany

    Dec 1, 2022, 00:00

  • CO177 Association Between the Sarcomatoid Status and Percentage of Sarcomatoid on the Clinical Outcomes of Localized Renal Cell Carcinoma Post Nephrectomy

    Dec 1, 2022, 00:00

  • EE551 Cost Benefits of Ibuprofen Ready to Use Solution Versus IV Drugs in Postoperative Analgesia

    Dec 1, 2022, 00:00

  • SA68 Protocol for the First Global Study Capturing the Patient-Reported Impact of Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia (ALSP) in the Real-World Setting Using a Smartphone Application

    Dec 1, 2022, 00:00

  • SA59 Is There Life for Pre-Prints After COVID-19?

    Dec 1, 2022, 00:00

  • RWD70 Electronic Implementation of Patient-Reported Outcomes: Challenges and Potential Solutions

    Dec 1, 2022, 00:00

  • PCR33 Health State Utilities for Woman With Breast Cancer in Portugal

    Dec 1, 2022, 00:00

  • EPH100 Ergonomic Benefits of 3D Visualization for Ophthalmic Surgeons

    Dec 1, 2022, 00:00

  • P16 Antineoplastic Agents in Ovarian Cancer Treatment Using Argentinian Real-World Data: OCEANIA Study

    Dec 1, 2022, 00:00

  • HPR95 Opportunities and Challenges for Value Added Medicines: Results of a Scoping Research Based on Expert Interviews

    Dec 1, 2022, 00:00

  • EE547 Cost-Effectiveness Analysis of Rituximab for Chronic Lymphocytic Leukemia Using a Semi-Markovian Model Approach in R

    Dec 1, 2022, 00:00

  • HTA3 The Clinical and Economic Value of a Sustained Response in the Treatment of Moderate-to-Severe Psoriasis in Spain: The PSOVALUE Project

    Dec 1, 2022, 00:00

  • HTA79 Time-Driven Activity-Based Costing to Compare the Cost of Administering Bronchodilators by Metered Dose Inhalers and by Nebulization in the Emergency Department

    Dec 1, 2022, 00:00

  • Key Trends in HTA Policy: Present and Future

    Dec 1, 2022, 00:00

  • PCR219 Women's Knowledge About Breast Cancer Screening in Hungary

    Dec 1, 2022, 00:00

  • HPR138 Comparing and Contrasting Early Access Opportunities Across the EU4 and UK

    Dec 1, 2022, 00:00

  • EE240 Does Single Stage Surgery of Long Bone Infection Using Gentamicin-Eluting Bone-Graft Substitutes Result in Decreased Cost and Improved Quality of Life Compared to Traditional Approaches?

    Dec 1, 2022, 00:00

  • EE254 A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients With Inflammatory Bowel Disease in Italy

    Dec 1, 2022, 00:00

  • EE531 Cost-Utility Analysis of Once-Weekly Semaglutide Versus Dulaglutide in Patients With Type 2 Diabetes Requiring Treatment With a GLP-1 Receptor Agonist

    Dec 1, 2022, 00:00

  • HSD93 Investigating the Impact of COVID-19 on Haemodialysis

    Dec 1, 2022, 00:00

  • MSR35 Systematically Validating Health Economic Models Using the Probabilistic Analysis Check Dashboard (PACBOARD)

    Dec 1, 2022, 00:00

  • MSR9 A Systematic Literature Review of the Economic and Humanistic Burden of Duchenne Muscular Dystrophy

    Dec 1, 2022, 00:00

  • HPR52 TNF-Alfa Inhibitor Therapies: Evaluating the Impact of Biosimilars Competition in Italy, Portugal and Spain

    Dec 1, 2022, 00:00

  • EE105 Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients With Haemophilia B Without Inhibitors

    Dec 1, 2022, 00:00

  • HTA28 Use of Synthetic Data Derived From Electronic Health Records to Augment Clinical Trial Data Evaluating First Line Therapy in Malignant Pleural Mesothelioma

    Dec 1, 2022, 00:00

  • EE271 Health State Utility Values Used in Economic Evaluation of Meningococcal Vaccination: A Systematic Review

    Dec 1, 2022, 00:00

  • HSD116 Bullous Pemphigoid Disease Activity and Initiation of Systemic Therapy in the Real-World Setting

    Dec 1, 2022, 00:00

  • PCR107 General and Scalable Versus Disease-Specific and Targeted: To What Extent Should We Measure Outcomes From These Two Areas?

    Dec 1, 2022, 00:00

  • MT17 The Value of Next Generation Sequencing for Lung Cancer in Europe: Findings From a Literature Review

    Dec 1, 2022, 00:00

  • MSR33 Application and Feasibility of Indirect Treatment Comparison of Switch Maintenance and Non-Maintenance Oncology Regimens to Inform HTA Decision-Making

    Dec 1, 2022, 00:00

  • SA57 Differences in Low Back Pain Knowledge Between Cultures: The Instance of Chinese and Hungarian Adults

    Dec 1, 2022, 00:00

  • P34 Subclinical Hypothyroidism Influences the Quality of Life During Pregnancy: Results From THYPREQOL2020

    Dec 1, 2022, 00:00

  • HTA111 Health Technology Assessment on Thermalytix; A Novel Breast Cancer Screening Technology

    Dec 1, 2022, 00:00

  • HTA263 Evaluation of the UK Innovative Licensing and Access Pathway

    Dec 1, 2022, 00:00

  • MSR116 Multivariate Associations between Health Outcomes and Health System Performance Indicators: An Integrated Factor Analysis with Canonical Correlations

    Dec 1, 2022, 00:00

  • HPR124 Utilising Health Economics to Enable Optimal Transition From a Platform Technology to a Development Programme and Product

    Dec 1, 2022, 00:00

  • PCR120 Psychometric Properties of the Hungarian PROMIS Global Health Questionnaire

    Dec 1, 2022, 00:00

  • P68 Investing in the Prevention of Infectious Disease Outbreaks: Fiscal Health Modelling for Assessing the Public Investment Case

    Dec 1, 2022, 00:00

  • PCR98 Cultural Adaptation of the Life Interference Questionnaire for Growth Hormone Deficiency (LIQ-GHD) into Spanish

    Dec 1, 2022, 00:00

  • RWD94 A Retrospective Study of Treatment Disparities in Demographics for Major Depressive Disorder (MDD) Using Claims Data in the US

    Dec 1, 2022, 00:00

  • CO171 Use of Patient-Reported Outcomes (PROs) and Its Implementation in Clinical Care in India: A Clinician's Perspective

    Dec 1, 2022, 00:00

  • MT26 A Literature Review on Health Economic Evaluation of Pipeline Embolization Device (PED) in Treating Intracranial Aneurysms

    Dec 1, 2022, 00:00

  • COVIDnomics

    Dec 1, 2022, 00:00

  • PCR71 Off Episode Quality of Life Impact Scale (OFFELIA): Overview of the Development of a Quality of Life and Functional Impact Measure of Off Episodes in Parkinson's Disease

    Dec 1, 2022, 00:00

  • HTA136 Impact on Scottish Medicines Consortium Reimbursement Decisions When Assessed Under the Orphan Drug Process

    Dec 1, 2022, 00:00

  • HSD100 A Multidisciplinary and Pharmacological Approach to the Treatment of Overweight and Obesity in a Health Maintenance Organization (HMO) in Brazil

    Dec 1, 2022, 00:00

  • MSR4 Data Visualization in Real-World Studies to Aid Understanding and Interpretation

    Dec 1, 2022, 00:00

  • EE658 Budget Impact Analysis for Multi-Indication Targeted Therapy: A Case Study of Cabozantinib Cost-Saving in Algeria as Treatment Option in First-Line Second-Line Renal-Cell Carcinoma and Second-Line Hepatocellular Carcinoma

    Dec 1, 2022, 00:00

  • EE294 Cost-Effectiveness of Left Ventricular Assist Devices as Destination Therapy: An Economic Modelling Study

    Dec 1, 2022, 00:00

  • HTA127 What Does the NICE Severity Modifier Mean in Reality? Has Cost Neutrality Restricted It Too Much?

    Dec 1, 2022, 00:00

  • EE611 A Cost-Minimization and Budget Impact Analysis to Evaluate the Introduction of an Acellular Hexavalent Vaccination for Pediatric Population in Dominican Republic

    Dec 1, 2022, 00:00

  • MT18 Patient Acceptance to Valuing Digital Technologies: A Discrete Choice Experiment

    Dec 1, 2022, 00:00

  • EE538 Cost Analysis, Cost-Effectiveness, and Cost-Utility of Hypertension and Hyperlipidemia Collaborative Management Between Pharmacies and Primary Care in Portugal Alongside a Trial Compared With Usual Care (USFarmácia®)

    Dec 1, 2022, 00:00

  • EE430 Cost-Effectiveness of Faricimab in Patients With Diabetic Macular Edema in Canada

    Dec 1, 2022, 00:00

  • HTA63 Implementation and Application of the Physician Information System (Arztinformationssystem, AIS) in Germany

    Dec 1, 2022, 00:00

  • PCR148 Patient Involvement in the Development of Outcomes Measures Specific to Neuronopathic Gaucher Disease Type 2 and Type 3 to Assess HRQoL Over the Disease Journey

    Dec 1, 2022, 00:00

  • EE452 Cost-Effectiveness Analysis of Introducing Ceftazidime-Avibactam to Treatment Strategies for Hospital-Acquired Infections in Greece

    Dec 1, 2022, 00:00

  • HTA105 Scope, Feasibility and Challenges of Valuing Disability in Cost-Effectiveness Analyses Submitted to the French National Authority for Health (HAS)

    Dec 1, 2022, 00:00

  • EPH99 Determinants of COVID-19 Vaccination in Hungary, Results of a Large Cross-Sectional Online Survey

    Dec 1, 2022, 00:00

  • EE306 Cost-Consequence Analysis of EPTFE Vascular Grafts With Heparin End Point Covalent Bond Compared to Standard EPTFE Vascular Grafts in Below-Knee Surgical Bypass for Critical Limb Ischemia Pad Patients in Germany

    Dec 1, 2022, 00:00

  • EPH208 Acquired Hemophilia A (AHA) – Trends in Frequency and Treatment Patterns in Germany

    Dec 1, 2022, 00:00

  • MSR50 Comparing Survival Extrapolation Outcomes Using Different Network Meta-Analyses (NMA) Methods: An Application in Patients With Metastatic Renal Cell Carcinoma (MRCC) Treated With Immunotherapy (IO) Based Combinations

    Dec 1, 2022, 00:00

  • HPR9 Trends in Direct Oral Anticoagulants (DOACS) Use in the Community Setting According to Their Accessibility Under National Health Basket in Israel: Real-World Data

    Dec 1, 2022, 00:00

  • EE126 Cost-Effectiveness of Multi-Cancer Early Detection (MCED) Testing Using Mixture Cure Modeling (MCM)

    Dec 1, 2022, 00:00

  • EE284 Cost-Effectiveness of Pembrolizumab in Combination With Chemotherapy As First-Line Treatment of Advanced or Metastatic Esophageal Cancer or HER2-Negative Gastroesophageal Junction Adenocarcinoma in France

    Dec 1, 2022, 00:00

  • Analyzing the Pain/Discomfort and Anxiety/Depression Composite Domains and the Meaning of Discomfort in the EQ-5D: A Mixed-Methods Study

    Dec 1, 2022, 00:00

  • HTA38 When and How Does RWE Impact HTA Outcomes in Oncology? A Qualitative Evaluation of Case Studies to Identify Drivers of RWE Acceptance Today and in the Future

    Dec 1, 2022, 00:00

  • SA64 Management of the Post-Surgery Hospital Care in France According to the Type of Surgery: A French Claims Database Analysis

    Dec 1, 2022, 00:00

  • CO64 Comparison of Propensity Score Matching to Inverse Probability Weighting in Obstructive Sleep Apnea Patients With Cardiovascular Diseases

    Dec 1, 2022, 00:00

  • EPH25 Premature Mortality From Ischaemic Heart Disease Among Women in Hungary by District

    Dec 1, 2022, 00:00

  • EPH38 Familial Hypercholesterolemia and Risk of Cardiovascular Disease: A Systematic Literature Review and Meta-Analysis of Observational Studies

    Dec 1, 2022, 00:00

  • PCR238 Oral Nutritional Supplementation in Pediatric Patients Diagnosed With Leukaemia Undergoing Chemotherapy: A Review of the Literature

    Dec 1, 2022, 00:00

  • EE439 Budgetary Impact of PCV20 Use Among Privately Insured Adult Patients Living in Dubai Who Are at Elevated Risk of Pneumococcal Disease

    Dec 1, 2022, 00:00

  • EE459 Early Intensification of Oral Semaglutide in the UK: A Cost-Effectiveness Analysis Versus Continuing Metformin and SGLT-2 Inhibitor Therapy

    Dec 1, 2022, 00:00

  • EE110 Psychological Impact of COVID-19 and the Economic Burden of Rheumatic and Musculoskeletal Diseases

    Dec 1, 2022, 00:00

  • HTA88 Similarities and Differences in Scientific Advice Processes

    Dec 1, 2022, 00:00

  • MSR66 Approaches to Control for Observable Selection Bias in Studies Including Staggered Treatment Timing

    Dec 1, 2022, 00:00

  • EE117 Understanding the Expected Severity Modifiers Across Diseases Following Changes to NICE Methodology

    Dec 1, 2022, 00:00

  • EE441 Health Economic Model for Estimating the Direct Cost Impact of Adopting an Antimicrobial Vascular Access Site Dressing in Oncology Patients With Central Venous Catheter in the UK

    Dec 1, 2022, 00:00

  • SA4 Effectiveness of Injury Prevention Primary Prevention Movement Program Among Handball Players

    Dec 1, 2022, 00:00

  • EE434 Health Care Resource Use and Costs in Transthyretin Amyloid Cardiomyopathy - A Swedish Medical Record Review Study

    Dec 1, 2022, 00:00

  • RWD50 Characteristics of Plaque Psoriasis Patients Initiating Biologics in the Real-World: Survey of Dermatology Practices Across the US and EU5 Countries

    Dec 1, 2022, 00:00

  • PCR151 Acceptability, Reliability, and Inconsistency in an Analytic Hierarchy Process-Survey With People Living With Dementia and Physicians: Analyses From the PreDemCare-Study

    Dec 1, 2022, 00:00

  • EE75 Cost-Effectiveness of Heart Failure Treatments– A Targeted Literature Review

    Dec 1, 2022, 00:00

  • HPR128 Suitability of Nordic Real-World Data to Support US Regulatory Decision-Making

    Dec 1, 2022, 00:00

  • CO162 Association Between Hypotension and Drug Interaction of Direct-Acting Antiviral Agents in Hepatitis C Virus-Infected Patients: A Multicenter Study in Taiwan

    Dec 1, 2022, 00:00

  • HTA12 Outpatient Medicine Reimbursement in Sweden: An Analysis of TLV Decisions Between 2016 and 2022

    Dec 1, 2022, 00:00

  • CO140 Costs and Healthcare Resource Utilization Among Patients With Lean Non-Alcoholic Steatohepatitis (NASH) Using Real-World Data (RWD)

    Dec 1, 2022, 00:00

  • RWD139 Impact of the COVID-19 Pandemic on Diagnosis and Cancer-Related Medical Procedures in Brazil

    Dec 1, 2022, 00:00

  • PCR14 A Literature Review of Methodology Used in In-Trial Interview Studies in Clinical Development

    Dec 1, 2022, 00:00

  • EPH147 A Joinpoint Regression Analysis of Food Supply Trends — Comparing Hungary to OECD Average

    Dec 1, 2022, 00:00

  • EPH137 CAR-T Cell Therapy: The State-of-the-Art of Evidence and Barriers in a Real-World Setting

    Dec 1, 2022, 00:00

  • EPH21 Obesity, a Public Health Threat in Gree Its Contribution to Future Cardiovascular Disease Burden

    Dec 1, 2022, 00:00

  • RWD132 Suitability of Nordic Real-World Data to Support EU Regulatory Decision Making

    Dec 1, 2022, 00:00

  • EE508 Work Productivity Loss Among Women With Menopausal Symptoms: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • PCR53 Patient Experiences Before and After Enfortumab Vedotin Neoadjuvant Treatment in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

    Dec 1, 2022, 00:00

  • HSD113 Reducing Antibiotic Misuse Through the Use of Point-of-Care Tests in Germany – A Multicenter Study

    Dec 1, 2022, 00:00

  • PCR122 Health-Related Quality of Life of Patients With Gall Bladder Cancer: A Targeted Review

    Dec 1, 2022, 00:00

  • HTA133 Comparing the Lifetime Survival in Patients With Early-Stage Hepatocellular Carcinoma Receiving Two Competitive Treatments: Liver Transplantation Versus Hepatic Resection

    Dec 1, 2022, 00:00

  • RWD24 Assessing the Performance of Propensity Score Methods in Balancing Unobservable Confounders: Evidence From Linked Data in Multiple Sclerosis

    Dec 1, 2022, 00:00

  • RWD72 Real-World Treatment Pathways of Patients With Diffuse Large B-Cell Lymphoma Receiving Second Line Treatment or Later in the UK, Canada, France, Germany, Italy, and Spain: A Prospective Survey of Physicians

    Dec 1, 2022, 00:00

  • MT40 Trends in Clinical Evidence for Digital Health Applications (DiGa) Reimbursed in the German DiGa Directory

    Dec 1, 2022, 00:00

  • EE638 Consumption of Stoma Appliances and Supporting Products Among Persons Living With a Stoma: A Swedish Register Study

    Dec 1, 2022, 00:00

  • MT41 Process and Requirements for Submitting Nonpharmaceutical Medical Technologies to Health Technology Assessment Authorities

    Dec 1, 2022, 00:00

  • MSR124 Development of a Machine Learning Predictive Model for Stroke Among Patients With Non-Valvular Atrial Fibrillation Receiving Oral Anticoagulant Treatment

    Dec 1, 2022, 00:00

  • SA60 Seeking ISPOR Abstracts: Is Searching Embase Enough?

    Dec 1, 2022, 00:00

  • Cover

    Dec 1, 2022, 00:00

  • PCR143 Project Hercules - Burden of Steroid Use in the Treatment of Duchenne Muscular Dystrophy: Findings From Patient and Carer Dyads and a Focus Group

    Dec 1, 2022, 00:00

  • EPH79 Examining the Health Behaviour of Young People

    Dec 1, 2022, 00:00

  • SA78 Agile Review of the Literature Using a Structured, Non-Systematic Approach: Example Application for a Genomic Diversity Question

    Dec 1, 2022, 00:00

  • EE449 Cost-Effectiveness of One Session Treatment (OST) for Children and Young People With Specific Phobias Compared to Multi-Session Cognitive Behavioural Therapy (CBT): Results From a Randomised Controlled Trial

    Dec 1, 2022, 00:00

  • CO172 Physical Activity and Health-Related Quality of Life of Patients With Chronic Pain After Total Knee Replacement: Evidence From a Physiotherapy Randomised Controlled Trial

    Dec 1, 2022, 00:00

  • RWD158 A Systematic Literature Review (SLR) of Clinical Practice Guidelines (CPGS) and Real-World Treatment Patterns in Metastatic Gastrointestinal Stromal Tumours (MGISTS) in Europe

    Dec 1, 2022, 00:00

  • EE175 Budget Impact Assessment of Knee Orthoses Funding in Patients With Osteoarthritis of the Knee Considering Total Knee Reconstructive Surgery: Private Australian Payer Perspective

    Dec 1, 2022, 00:00

  • EE435 First Time Ablation for Patients With Paroxysmal Atrial Fibrillation – Budget Impact of Different Modalities in the Real World

    Dec 1, 2022, 00:00

  • RWD17 A Retrospective Observational Study on the Healthcare Resource Use of Patients With Myasthenia Gravis in Secondary Care in England Using Hospital Episodes Statistics

    Dec 1, 2022, 00:00

  • EPH94 Impact of Patient Race on Insurance Payor Switch Rate, Healthcare Resource Utilization, and Cost Among Adult Patients With Schizophrenia in the United States: An Analysis of RWD Insights All-Payer Claims Database

    Dec 1, 2022, 00:00

  • EE160 Budget Impact Analysis for Point of Care Testing (POCT) in Diabetic Patient Monitoring: The Experience of an Italian Local Health Board (ASL3 Genoa, Italy)

    Dec 1, 2022, 00:00

  • HTA265 Perspectives of National Health-Related Quality of Life Measurement Implementation in Ukraine

    Dec 1, 2022, 00:00

  • EE322 Public Health Impact and Return on Investment of the Pediatric Immunization Program in Poland

    Dec 1, 2022, 00:00

  • RWD93 The Experience of Cancer Cooperative Groups With Real-World Data Research: Insights From an EORTC Survey

    Dec 1, 2022, 00:00

  • PCR30 An Empirical Comparison of EQ-5D-Y-5L and EQ-5D-Y 3L Questionnaires

    Dec 1, 2022, 00:00

  • RWD102 Electronic Health Records With Unstructured Text to Predict Outcomes With Machine Learning: A Therapeutic Area Fingerprint

    Dec 1, 2022, 00:00

  • CO91 Investigation of Conceptual Distinction Between Response Set Options - A Step Toward Obtaining Quality Data

    Dec 1, 2022, 00:00

  • EE169 Estimation of Value of Life for Turkiye With a Model Approach Depending on Net Present Value

    Dec 1, 2022, 00:00

  • HPR63 Estimates of the Global Burden of COVID-19 and the Value of Broad and Equitable Access to COVID-19 Vaccines

    Dec 1, 2022, 00:00

  • EPH50 The Public Health Impact of Routine Vaccination in 16-40-Year-Old Females for the Prevention of Cytomegalovirus and Congenital Cytomegalovirus in the United Kingdom

    Dec 1, 2022, 00:00

  • HTA256 Early Health Technology Assessment of the Lymphocyte Antigen 75 Biomarker for Cutaneous Melanoma

    Dec 1, 2022, 00:00

  • Does the Choice of Cost-Effectiveness Model Approach Matter?

    Dec 1, 2022, 00:00

  • HPR206 When It Comes to Incentives for Antimicrobial Development – Is a United Front Essential?

    Dec 1, 2022, 00:00

  • EE131 Cost-Effectiveness Analysis of Emergency Department-Based HCV Screening and Linkage-to-Care Program

    Dec 1, 2022, 00:00

  • Editorial Board

    Nov 12, 2022, 08:58

  • Editorial Board

    Nov 3, 2022, 17:50

  • The Hip Disability and Osteoarthritis Outcome Score-Physical Function Shortform Does Not Adequately Represent Physical Functioning in Patients Undergoing Total Hip Arthroplasty

    Nov 1, 2022, 00:00

  • Cost-Effectiveness of Care Coordination for Children With Chronic Noncomplex Medical Conditions: Results From a Multicenter Randomized Clinical Trial

    Nov 1, 2022, 00:00

  • Real Option Value: Should We Opt In or Out?

    Nov 1, 2022, 00:00

  • Why We Need a New Outcomes-Based Value Attribution Framework for Combination Regimens in Oncology [Editor's Choice]

    Nov 1, 2022, 00:00

  • Measurement Properties of the EQ-5D-Y: A Systematic Review [Editor's Choice]

    Nov 1, 2022, 00:00

  • Table of Contents

    Nov 1, 2022, 00:00

  • Body of Evidence for Onasemnogene Abeparvovec in Spinal Muscular Atrophy Supports Long-Term Duration of Effect Without Relapse

    Nov 1, 2022, 00:00

  • Association Between Receipt of Definitive Treatment for Localized Prostate Cancer and Adverse Health Outcomes: A Claims-Based Approach

    Nov 1, 2022, 00:00

  • Modeling the Recovery of Elective Waiting Lists Following COVID-19: Scenario Projections for England

    Nov 1, 2022, 00:00

  • The Garbage Class Mixed Logit Model: Accounting for Low-Quality Response Patterns in Discrete Choice Experiments

    Nov 1, 2022, 00:00

  • Access to Disease-Modifying Alzheimer’s Therapies: Addressing Possible Challenges Using Innovative Payment Models

    Nov 1, 2022, 00:00

  • No Time to Waste: An Appraisal of Value at the End of Life [Editor's Choice]

    Nov 1, 2022, 00:00

  • Copyright/Subscription

    Nov 1, 2022, 00:00

  • The National Hospital Care Survey Is a Unique Source of Data on Rare Diseases

    Nov 1, 2022, 00:00

  • Using Patient-Reported Outcome Measures to Evaluate Care for Patients With Inflammatory Chronic Rheumatic Disease

    Nov 1, 2022, 00:00

  • A Comprehensive Comparison of Additional Benefit Assessment Methods Applied by Institute for Quality and Efficiency in Health Care and European Society for Medical Oncology for Time-to-Event Endpoints After Significant Phase III Trials—A Si ...

    Nov 1, 2022, 00:00

  • A Pragmatic Guide to Assessing Real Option Value for Medical Technologies [Editor's Choice]

    Nov 1, 2022, 00:00

  • A Simulation-Based Cost-Effectiveness Analysis of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Prevention Strategies for Visitors of Healthcare Institutions

    Nov 1, 2022, 00:00

  • Editorial Board

    Oct 5, 2022, 08:50

  • How Do Treatment Preferences of Patients With Cancer Compare With Those of Oncologists and Family Members? Evidence From a Discrete Choice Experiment in China

    Oct 1, 2022, 00:00

  • Strengthening the Interface of Evidence-Based Decision Making Across European Regulators and Health Technology Assessment Bodies [Editor's Choice]

    Oct 1, 2022, 00:00

  • Copyright/Subscription

    Oct 1, 2022, 00:00

  • State Laws and Generic Substitution in the Year After New Generic Competition

    Oct 1, 2022, 00:00

  • Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in The Netherlands

    Oct 1, 2022, 00:00

  • Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic Leukemia

    Oct 1, 2022, 00:00

  • Common Patient-Reported Outcomes Within the Food and Drug Administration Voice of the Patient Reports [Editor's Choice]

    Oct 1, 2022, 00:00

  • Prevalence and Risk Factors of Primary Dysmenorrhea in Students: A Meta-Analysis

    Oct 1, 2022, 00:00

  • A Systematic Review of International Guidance for Self-Report and Proxy Completion of Child-Specific Utility Instruments

    Oct 1, 2022, 00:00

  • Frequently Used Patient-Reported Outcome Measures of General Physical Function Were Highly Correlated With a Multitask Performance Outcome Test Battery

    Oct 1, 2022, 00:00

  • Suprachoroidal Injection of Triamcinolone Acetonide Injectable Suspension for the Treatment of Macular Edema Associated With Uveitis in the United States: A Cost-Effectiveness Analysis

    Oct 1, 2022, 00:00

  • HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force [Editor's Choice]

    Oct 1, 2022, 00:00

  • Moving Beyond Quality-Adjusted Life-Years in Elderly Care: How Can Multicriteria Decision Analysis Complement Cost-Effectiveness Analysis in Local-Level Decision Making

    Oct 1, 2022, 00:00

  • Value of Nonpharmacological Interventions for People With an Acquired Brain Injury: A Systematic Review of Economic Evaluations

    Oct 1, 2022, 00:00

  • Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools

    Oct 1, 2022, 00:00

  • Table of Contents

    Oct 1, 2022, 00:00

  • Estimating Quality of Life Decrements in Oncology Using Time to Death

    Oct 1, 2022, 00:00

  • Did the Integrated Urban and Rural Resident Basic Medical Insurance Improve Benefit Equity in China? [Editor's Choice]

    Sep 1, 2022, 00:00

  • Healthcare Costs for Pneumococcal Disease in the Era of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine: A Population-Based Study

    Sep 1, 2022, 00:00

  • How Useful Are Digital Health Terms for Outcomes Research? An ISPOR Special Interest Group Report

    Sep 1, 2022, 00:00

  • Copyright/Subscription

    Sep 1, 2022, 00:00

  • Where Are Populations Aging Better? A Global Comparison of Healthy Aging Across Organization for Economic Cooperation and Development Countries [Editor's Choice]

    Sep 1, 2022, 00:00

  • Systematic Review of Cost-Utility Analyses That Have Included Carer and Family Member Health-Related Quality of Life

    Sep 1, 2022, 00:00
  • «
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38 (current)
  • 39
  • 40
  • »